Payment overview · 2025
General Payments
$1,324.16
74 reported records · 12 companies
Healthcare provider profile · identity verified
Kenneth Weiser, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · WHITE PLAINS, NY · NPI 1104886589
Verified facts
What the public records show
CMS Open Payments records show Kenneth Weiser, M.D. received $1,324.16 in general payments during 2025 across 74 reported records.
BETA BIONICS, INC. accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 459 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 459 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 466 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 663 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $301.95 | 22.8% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $262.87 | 19.9% | 14 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $171.14 | 12.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.21 | 10.5% | 6 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $135.03 | 10.2% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $82.09 | 6.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.80 | 5.3% | 4 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $46.96 | 3.5% | 4 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $32.84 | 2.5% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $32.36 | 2.4% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $28.88 | 2.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.03 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,324.16 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $301.95 | 16 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $301.95 | 16 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $301.95 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $217.22 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $171.14 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $164.22 | 9 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $135.03 | 12 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $114.84 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $82.09 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.80 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.80 | 4 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $46.96 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.65 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $32.84 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $28.88 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 459 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 466 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 663 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 186 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
459 | 112 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
459 | 112 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
466 | 74 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
161 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
663 | 115 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
186 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 829 | 223 |
| Metformin Hcl | Metformin Hcl | 731 | 214 |
| Atorvastatin Calcium | Atorvastatin Calcium | 709 | 187 |
| Ozempic | Semaglutide | 663 | 115 |
| Glimepiride | Glimepiride | 639 | 171 |
| Metformin Hcl Er | Metformin Hcl | 476 | 120 |
| Mounjaro | Tirzepatide | 466 | 74 |
| Jardiance | Empagliflozin | 459 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 80 |
| Synthroid | Levothyroxine Sodium | 248 | 74 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 236 | 83 |
| Glipizide Er | Glipizide | 219 | 65 |
| Farxiga | Dapagliflozin Propanediol | 206 | 47 |
| Simvastatin | Simvastatin | 206 | 54 |
| Pioglitazone Hcl | Pioglitazone Hcl | 193 | 53 |
| Rybelsus | Semaglutide | 186 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 53 |
| Losartan Potassium | Losartan Potassium | 180 | 47 |
| Tresiba Flextouch U-100 | Insulin Degludec | 174 | 54 |
| Ramipril | Ramipril | 168 | 47 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 162 | 60 |
| Trulicity | Dulaglutide | 161 | 34 |
| Lisinopril | Lisinopril | 142 | 39 |
| Humalog Kwikpen U-100 | Insulin Lispro | 131 | 55 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 128 | 52 |
| Novolog Flexpen | Insulin Aspart | 117 | 44 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 108 | 29 |
| Risedronate Sodium | Risedronate Sodium | 94 | 37 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 91 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 26 |
| Omeprazole | Omeprazole | 88 | 25 |
| Methimazole | Methimazole | 87 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 22 |
| Levemir Flexpen | Insulin Detemir | 66 | 19 |
| Ezetimibe | Ezetimibe | 56 | 17 |
| Valsartan | Valsartan | 56 | 13 |
| Januvia | Sitagliptin Phosphate | 55 | 17 |
| Testosterone | Testosterone | 55 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 55 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | suppressed |
| Allopurinol | Allopurinol | 54 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 51 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 13 |
| Alprazolam | Alprazolam | 49 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | 14 |
| Atenolol | Atenolol | 43 | 11 |
| Enalapril Maleate | Enalapril Maleate | 42 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Humalog | Insulin Lispro | 41 | 16 |
| Tradjenta | Linagliptin | 41 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 38 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 37 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 36 | suppressed |
| Novolog | Insulin Aspart | 36 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 33 | 11 |
| Repaglinide | Repaglinide | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Gabapentin | Gabapentin | 30 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Furosemide | Furosemide | 28 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 25 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 21 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Teriparatide | Teriparatide | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Acarbose | Acarbose | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 14 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 11 | suppressed |
| Segluromet | Ertugliflozin/Metformin | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,324.16 · 74 records | BETA BIONICS, INC. | AFREZZA, CeQur Simplicity, EVENITY, FREESTYLE LIBRE, JARDIANCE, MOUNJARO, Omnipod, Ozempic, PROLIA, Rybelsus, Saxenda, TEPEZZA, TWIIST, Wegovy, XYOSTED, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error